-
Posted by
Two Blokes Fri at 1:00 PM -
Filed in
Stock
-
2 views
SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it has entered into a new loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”).
